AAAAAA

   
Results: 1-18 |
Results: 18
ORAL DOLASETRON MESYLATE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Authors: DIEMUNSCH P KORTTILA K LEESER J HELMERS JHJH WILKEY B NAVE S RADKE AJ HAHNE WF BROWN RA
Citation: P. Diemunsch et al., ORAL DOLASETRON MESYLATE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, Journal of clinical anesthesia, 10(2), 1998, pp. 145-152
RATIONALE FOR THE USE OF A SINGLE FIXED INTRAVENOUS DOLASETRON DOSE FOR THE PREVENTION OF CISPLATIN-INDUCED NAUSEA AND VOMITING - POOLED ANALYSIS OF 14 CLINICAL-TRIALS
Authors: WHITMORE JB KRIS MG HESKETH PJ GROTE TH DUBOIS DM CRAMER MB HAHNE WF
Citation: Jb. Whitmore et al., RATIONALE FOR THE USE OF A SINGLE FIXED INTRAVENOUS DOLASETRON DOSE FOR THE PREVENTION OF CISPLATIN-INDUCED NAUSEA AND VOMITING - POOLED ANALYSIS OF 14 CLINICAL-TRIALS, Supportive care in cancer, 6(5), 1998, pp. 473-478
ORAL DOLASETRON MESYLATE IN PATIENTS RECEIVING MODERATELY EMETOGENIC PLATINUM-CONTAINING CHEMOTHERAPY
Authors: GROTE TH PINEDA LF FIGLIN RA PENDERGRASS KB HESKETH PJ KARLAN BY REEVES JA PORTER LL BENEDICT CR HAHNE WF
Citation: Th. Grote et al., ORAL DOLASETRON MESYLATE IN PATIENTS RECEIVING MODERATELY EMETOGENIC PLATINUM-CONTAINING CHEMOTHERAPY, The cancer journal from Scientific American, 3(1), 1997, pp. 45-51
INTRAVENOUS DOLASETRON MESILATE IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN FEMALES UNDERGOING GYNECOLOGICAL SURGERY
Authors: DIEMUNSCH P DHOLLANDER A PAXTON L SCHOEFFLER P WESSEL P NAVE S BROWN RA HAHNE WF
Citation: P. Diemunsch et al., INTRAVENOUS DOLASETRON MESILATE IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN FEMALES UNDERGOING GYNECOLOGICAL SURGERY, Journal of clinical anesthesia, 9(5), 1997, pp. 365-373
INTRAVENOUS DOLASETRON MESILATE AMELIORATES POSTOPERATIVE NAUSEA AND VOMITING
Authors: DIEMUNSCH P LEESER J FEISS P DHOLLANDER A BRADBURN BG PAXTON D WHITMORE J PANOUILLOT P NAVE S BROWN RA HAHNE WF
Citation: P. Diemunsch et al., INTRAVENOUS DOLASETRON MESILATE AMELIORATES POSTOPERATIVE NAUSEA AND VOMITING, Canadian journal of anaesthesia, 44(2), 1997, pp. 173-181
A DOUBLE-BLIND, RANDOMIZED STUDY OF 2 DIFFERENT DOSAGE REGIMENS OF INTRAVENOUS DOLASETRON IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN CHEMOTHERAPY
Authors: KASIMIS BS TAPAZOGLOU E SCHULMAN P STEWART WH HAHNE WF CRAMER MB
Citation: Bs. Kasimis et al., A DOUBLE-BLIND, RANDOMIZED STUDY OF 2 DIFFERENT DOSAGE REGIMENS OF INTRAVENOUS DOLASETRON IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN CHEMOTHERAPY, Cancer investigation, 15(4), 1997, pp. 304-310
PHARMACOKINETICS OF DOLASETRON AFTER ORAL AND INTRAVENOUS ADMINISTRATION OF DOLASETRON MESYLATE IN HEALTHY-VOLUNTEERS AND PATIENTS WITH HEPATIC-DYSFUNCTION
Authors: STUBBS K MARTIN LA DIMMITT DC PREADY N HAHNE WF
Citation: K. Stubbs et al., PHARMACOKINETICS OF DOLASETRON AFTER ORAL AND INTRAVENOUS ADMINISTRATION OF DOLASETRON MESYLATE IN HEALTHY-VOLUNTEERS AND PATIENTS WITH HEPATIC-DYSFUNCTION, Journal of clinical pharmacology, 37(10), 1997, pp. 926-936
RANDOMIZED, DOUBLE-BLIND, DOSE-RESPONSE TRIAL ACROSS 4 ORAL DOSES OF DOLASETRON FOR THE PREVENTION OF ACUTE EMESIS AFTER MODERATELY EMETOGENIC CHEMOTHERAPY
Authors: RUBENSTEIN EB GRALLA RJ HAINSWORTH JD HESKETH PJ GROTE TH MODIANO MR KHOJASTEH A KALMAN LA BENEDICT CR HAHNE WF
Citation: Eb. Rubenstein et al., RANDOMIZED, DOUBLE-BLIND, DOSE-RESPONSE TRIAL ACROSS 4 ORAL DOSES OF DOLASETRON FOR THE PREVENTION OF ACUTE EMESIS AFTER MODERATELY EMETOGENIC CHEMOTHERAPY, Cancer, 79(6), 1997, pp. 1216-1224
TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING WITH SINGLE INTRAVENOUS DOSES OF DOLASETRON MESYLATE - A MULTICENTER TRIAL
Authors: KOVAC AL SCUDERI PE BOERNER TF CHELLY JE GOLDBERG ME HANTLER CB HAHNE WF BROWN RA
Citation: Al. Kovac et al., TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING WITH SINGLE INTRAVENOUS DOSES OF DOLASETRON MESYLATE - A MULTICENTER TRIAL, Anesthesia and analgesia, 85(3), 1997, pp. 546-552
INTRAVENOUS DOLASETRON FOR THE PREVENTION OF POSTOPERATIVE NAUSEA ANDVOMITING AFTER OUTPATIENT LAPAROSCOPIC GYNECOLOGIC SURGERY
Authors: GRACZYK SG MCKENZIE R KALLAR S HICKOK CB MELSON T MORRILL B HAHNE WF BROWN RA
Citation: Sg. Graczyk et al., INTRAVENOUS DOLASETRON FOR THE PREVENTION OF POSTOPERATIVE NAUSEA ANDVOMITING AFTER OUTPATIENT LAPAROSCOPIC GYNECOLOGIC SURGERY, Anesthesia and analgesia, 84(2), 1997, pp. 325-330
DOSE-RANGING EVALUATION OF THE ANTIEMETIC EFFICACY OF INTRAVENOUS DOLASETRON IN PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN OR CYCLOPHOSPHAMIDE
Authors: HESKETH PJ GANDARA DR HESKETH AM FACADA A PEREZ EA WEBBER LM MARTIN LA CRAMER MB HAHNE WF
Citation: Pj. Hesketh et al., DOSE-RANGING EVALUATION OF THE ANTIEMETIC EFFICACY OF INTRAVENOUS DOLASETRON IN PATIENTS RECEIVING CHEMOTHERAPY WITH DOXORUBICIN OR CYCLOPHOSPHAMIDE, Supportive care in cancer, 4(2), 1996, pp. 141-146
A RANDOMIZED, DOUBLE-BLIND COMPARISON OF SINGLE-DOSE AND DIVIDED MULTIPLE-DOSE DOLASETRON FOR CISPLATIN-INDUCED EMESIS
Authors: HARMAN GS OMURA GA RYAN K HAINSWORTH JD CRAMER MB HAHNE WF
Citation: Gs. Harman et al., A RANDOMIZED, DOUBLE-BLIND COMPARISON OF SINGLE-DOSE AND DIVIDED MULTIPLE-DOSE DOLASETRON FOR CISPLATIN-INDUCED EMESIS, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 323-328
ANTIEMETIC EFFICACY OF 2 DIFFERENT SINGLE INTRAVENOUS DOSES OF DOLASETRON IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN-CONTAINING CHEMOTHERAPY
Authors: YEILDING A BERTOLI L EISENBERG P PLEZIA P MODIANO MR ALBERTS DS KHOJASTEH A CRAMER MB HAHNE WF
Citation: A. Yeilding et al., ANTIEMETIC EFFICACY OF 2 DIFFERENT SINGLE INTRAVENOUS DOSES OF DOLASETRON IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN-CONTAINING CHEMOTHERAPY, American journal of clinical oncology, 19(6), 1996, pp. 619-623
SINGLE-DOSE, PLACEBO-CONTROLLED, PHASE-I STUDY OF ORAL DOLASETRON
Authors: DIXON RM CRAMER M SHAH AK WHITMORE J BENEDICT CR HAHNE WF
Citation: Rm. Dixon et al., SINGLE-DOSE, PLACEBO-CONTROLLED, PHASE-I STUDY OF ORAL DOLASETRON, Pharmacotherapy, 16(2), 1996, pp. 245-252
MULTIPLE-DOSE, PLACEBO-CONTROLLED, PHASE-I STUDY OF ORAL DOLASETRON
Authors: HUNT TL CRAMER M CHRISTYBITTEL J SHAH AK MEYERSON LJ BENEDICT CR HAHNE WF
Citation: Tl. Hunt et al., MULTIPLE-DOSE, PLACEBO-CONTROLLED, PHASE-I STUDY OF ORAL DOLASETRON, Pharmacotherapy, 16(2), 1996, pp. 253-260
A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING SAFETY EVALUATION OFSINGLE-DOSE INTRAVENOUS DOLASETRON IN HEALTHY MALE-VOLUNTEERS
Authors: HUNT TL CRAMER M SHAH A STEWART W BENEDICT CR HAHNE WF
Citation: Tl. Hunt et al., A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING SAFETY EVALUATION OFSINGLE-DOSE INTRAVENOUS DOLASETRON IN HEALTHY MALE-VOLUNTEERS, Journal of clinical pharmacology, 35(7), 1995, pp. 705-712
DOSE-RANGING EVALUATION OF THE SEROTONIN ANTAGONIST DOLASETRON MESYLATE IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN
Authors: KRIS MG GRUNBERG SM GRALLA RJ BALTZER L ZARETSKY SA LIFSEY D TYSON LB SCHMIDT L HAHNE WF
Citation: Mg. Kris et al., DOSE-RANGING EVALUATION OF THE SEROTONIN ANTAGONIST DOLASETRON MESYLATE IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN, Journal of clinical oncology, 12(5), 1994, pp. 1045-1049
PARENTERAL CONTROL OF GASTRIC-ACID HYPERSECRETION IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME
Authors: VINAYEK R HAHNE WF EULER AR NORTON JA JENSEN RT
Citation: R. Vinayek et al., PARENTERAL CONTROL OF GASTRIC-ACID HYPERSECRETION IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME, Digestive diseases and sciences, 38(10), 1993, pp. 1857-1865
Risultati: 1-18 |